Symbols / LUNG $1.33 +3.91% Pulmonx Corporation
LUNG Chart
About
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 56.18M |
| Enterprise Value | 42.79M | Income | -54.00M | Sales | 90.50M |
| Book/sh | 1.30 | Cash/sh | 1.65 | Dividend Yield | — |
| Payout | 0.00% | Employees | 296 | IPO | — |
| P/E | — | Forward P/E | -1.32 | PEG | — |
| P/S | 0.62 | P/B | 1.02 | P/C | — |
| EV/EBITDA | -0.81 | EV/Sales | 0.47 | Quick Ratio | 4.11 |
| Current Ratio | 5.07 | Debt/Eq | 104.15 | LT Debt/Eq | — |
| EPS (ttm) | -1.33 | EPS next Y | -1.01 | EPS Growth | — |
| Revenue Growth | -4.90% | Earnings | 2026-04-29 | ROA | -22.96% |
| ROE | -77.19% | ROIC | — | Gross Margin | 74.19% |
| Oper. Margin | -43.82% | Profit Margin | -59.67% | Shs Outstand | 42.24M |
| Shs Float | 37.39M | Short Float | 11.26% | Short Ratio | 4.64 |
| Short Interest | — | 52W High | 7.01 | 52W Low | 1.13 |
| Beta | 0.19 | Avg Volume | 505.54K | Volume | 178.77K |
| Target Price | $5.17 | Recom | None | Prev Close | $1.28 |
| Price | $1.33 | Change | 3.91% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2026-03-05 | main | D. Boral Capital | Buy → Buy | $14 |
| 2026-02-20 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-11-13 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-10-28 | main | Lake Street | Buy → Buy | $4 |
| 2025-10-28 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-09-08 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-08-01 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-07-31 | main | Lake Street | Buy → Buy | $8 |
| 2025-07-31 | main | Stifel | Buy → Buy | $5 |
| 2025-07-31 | down | Piper Sandler | Overweight → Neutral | $3 |
| 2025-07-31 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-22 | main | Citigroup | Neutral → Neutral | $4 |
| 2025-05-01 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2025-05-01 | reit | Piper Sandler | Overweight → Overweight | $9 |
| 2025-05-01 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-03-11 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-03-10 | init | D. Boral Capital | — → Buy | $17 |
| 2025-02-20 | main | Citigroup | Neutral → Neutral | $8 |
| 2024-12-11 | main | Wells Fargo | Equal-Weight → Equal-Weight | $8 |
- LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - chartmill.com hu, 02 Apr 2026 07
- Pulmonx Insiders Forfeit On 14% Gains After Selling Stock - simplywall.st Sun, 05 Apr 2026 12
- How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance - finance.yahoo.com Sun, 05 Apr 2026 00
- United Therapeutics Stock Hits 52-Week High on Successful Lung Disease Drug Trial - TIKR.com ue, 31 Mar 2026 12
- AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed - CNBC Fri, 27 Mar 2026 07
- $LUNG stock is up 11% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Mar 2026 08
- Device for severe emphysema: Pulmonx secures up to $60M credit line - Stock Titan Wed, 04 Mar 2026 08
- Barry Manilow Details Lung Cancer Diagnosis and Treatment, Says It 'Made Me Take Stock of My Life' at 82 (Exclusive) - People.com ue, 24 Mar 2026 07
- Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In? - finance.yahoo.com Fri, 31 Oct 2025 07
- Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan Wed, 04 Mar 2026 08
- $LUNG stock is up 14% today. Here's what we see in our data. - Quiver Quantitative ue, 09 Dec 2025 08
- If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan Sun, 22 Mar 2026 04
- What Makes Pulmonx (LUNG) a New Buy Stock - finance.yahoo.com Wed, 27 Aug 2025 07
- $LUNG stock is up 39% today. Here's what we see in our data. - Quiver Quantitative ue, 28 Oct 2025 07
- Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG) - Stock Titan Fri, 27 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
90.50
+8.01%
|
83.79
+22.01%
|
68.67
+27.98%
|
53.66
|
| Operating Revenue |
|
90.50
+8.01%
|
83.79
+22.01%
|
68.67
+27.98%
|
53.66
|
| Cost Of Revenue |
|
23.36
+7.21%
|
21.79
+21.56%
|
17.92
+29.91%
|
13.80
|
| Reconciled Cost Of Revenue |
|
23.36
+7.21%
|
21.79
+21.56%
|
17.92
+29.91%
|
13.80
|
| Gross Profit |
|
67.14
+8.29%
|
62.00
+22.16%
|
50.75
+27.31%
|
39.87
|
| Operating Expense |
|
120.80
+0.92%
|
119.70
+6.23%
|
112.69
+14.40%
|
98.50
|
| Research And Development |
|
19.49
+10.93%
|
17.57
-2.82%
|
18.08
+17.43%
|
15.40
|
| Selling General And Administration |
|
101.31
-0.81%
|
102.14
+7.96%
|
94.61
+13.84%
|
83.11
|
| Total Expenses |
|
144.16
+1.88%
|
141.49
+8.33%
|
130.61
+16.31%
|
112.30
|
| Operating Income |
|
-53.66
+7.00%
|
-57.70
+6.83%
|
-61.94
-5.62%
|
-58.64
|
| Total Operating Income As Reported |
|
-53.66
+7.00%
|
-57.70
+6.83%
|
-61.94
-5.62%
|
-58.64
|
| EBITDA |
|
-49.17
+3.39%
|
-50.89
+8.29%
|
-55.49
+0.89%
|
-55.99
|
| Normalized EBITDA |
|
-49.17
+3.39%
|
-50.89
+8.29%
|
-55.49
+0.89%
|
-55.99
|
| Reconciled Depreciation |
|
1.05
-29.40%
|
1.49
-3.55%
|
1.55
+2.31%
|
1.51
|
| EBIT |
|
-50.22
+4.13%
|
-52.39
+8.16%
|
-57.04
+0.81%
|
-57.50
|
| Net Income |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Pretax Income |
|
-53.38
+4.50%
|
-55.89
+7.26%
|
-60.27
-2.91%
|
-58.57
|
| Net Non Operating Interest Income Expense |
|
-0.50
-132.43%
|
1.55
-33.48%
|
2.34
+404.54%
|
0.46
|
| Interest Expense Non Operating |
|
3.15
-10.04%
|
3.51
+8.51%
|
3.23
+203.19%
|
1.07
|
| Net Interest Income |
|
-0.50
-132.43%
|
1.55
-33.48%
|
2.34
+404.54%
|
0.46
|
| Interest Expense |
|
3.15
-10.04%
|
3.51
+8.51%
|
3.23
+203.19%
|
1.07
|
| Interest Income Non Operating |
|
2.65
-47.62%
|
5.06
-9.11%
|
5.57
+264.16%
|
1.53
|
| Interest Income |
|
2.65
-47.62%
|
5.06
-9.11%
|
5.57
+264.16%
|
1.53
|
| Other Income Expense |
|
0.79
+208.59%
|
0.26
+138.04%
|
-0.67
-69.95%
|
-0.40
|
| Other Non Operating Income Expenses |
|
0.79
+208.59%
|
0.26
+138.04%
|
-0.67
-69.95%
|
-0.40
|
| Tax Provision |
|
0.63
+25.20%
|
0.50
-12.43%
|
0.57
+61.76%
|
0.35
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Net Income From Continuing Operation Net Minority Interest |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Net Income From Continuing And Discontinued Operation |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Net Income Continuous Operations |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Normalized Income |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Net Income Common Stockholders |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Diluted EPS |
|
-1.33
+7.64%
|
-1.44
+10.00%
|
-1.60
-0.63%
|
-1.59
|
| Basic EPS |
|
-1.33
+7.64%
|
-1.44
+10.00%
|
-1.60
-0.63%
|
-1.59
|
| Basic Average Shares |
|
40.69
+4.03%
|
39.11
+2.99%
|
37.97
+2.37%
|
37.10
|
| Diluted Average Shares |
|
40.69
+4.03%
|
39.11
+2.99%
|
37.97
+2.37%
|
37.10
|
| Diluted NI Availto Com Stockholders |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
129.29
-20.61%
|
162.85
-8.40%
|
177.78
-8.21%
|
193.68
|
| Current Assets |
|
101.68
-25.37%
|
136.25
-9.42%
|
150.42
-10.97%
|
168.95
|
| Cash Cash Equivalents And Short Term Investments |
|
69.75
-31.27%
|
101.48
-13.34%
|
117.10
-17.03%
|
141.14
|
| Cash And Cash Equivalents |
|
69.75
-1.63%
|
70.91
-15.13%
|
83.55
-17.88%
|
101.74
|
| Cash Equivalents |
|
1.04
-84.31%
|
6.62
-73.67%
|
25.13
+440.76%
|
4.65
|
| Cash Financial |
|
68.71
+6.88%
|
64.29
+10.05%
|
58.42
-39.83%
|
97.09
|
| Other Short Term Investments |
|
0.00
-100.00%
|
30.58
-8.87%
|
33.55
-14.84%
|
39.40
|
| Receivables |
|
12.66
-8.18%
|
13.79
+5.92%
|
13.02
+40.32%
|
9.28
|
| Accounts Receivable |
|
12.07
-7.99%
|
13.12
+8.38%
|
12.11
+39.51%
|
8.68
|
| Gross Accounts Receivable |
|
12.17
-7.93%
|
13.22
+9.21%
|
12.11
+37.92%
|
8.78
|
| Allowance For Doubtful Accounts Receivable |
|
-0.10
+0.00%
|
-0.10
|
0.00
+100.00%
|
-0.10
|
| Taxes Receivable |
|
0.59
-11.92%
|
0.67
-26.67%
|
0.92
+51.99%
|
0.60
|
| Inventory |
|
15.85
-6.33%
|
16.91
+1.03%
|
16.74
+14.96%
|
14.56
|
| Raw Materials |
|
—
|
—
|
—
|
—
|
| Work In Process |
|
—
|
—
|
—
|
—
|
| Finished Goods |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
2.68
+0.07%
|
2.67
-5.04%
|
2.82
-18.40%
|
3.45
|
| Restricted Cash |
|
0.26
+0.39%
|
0.26
+8.44%
|
0.24
+2.60%
|
0.23
|
| Other Current Assets |
|
0.49
-56.51%
|
1.13
+124.01%
|
0.50
+73.79%
|
0.29
|
| Total Non Current Assets |
|
27.61
+3.78%
|
26.60
-2.77%
|
27.36
+10.66%
|
24.72
|
| Net PPE |
|
20.25
-5.61%
|
21.45
+188.57%
|
7.43
-29.20%
|
10.50
|
| Gross PPE |
|
26.90
-1.02%
|
27.18
+121.14%
|
12.29
-12.57%
|
14.06
|
| Accumulated Depreciation |
|
-6.65
-16.18%
|
-5.72
-17.90%
|
-4.86
-36.53%
|
-3.56
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
6.48
+6.16%
|
6.11
+38.57%
|
4.41
+6.24%
|
4.15
|
| Construction In Progress |
|
0.05
-75.24%
|
0.21
-90.63%
|
2.20
+20.49%
|
1.82
|
| Other Properties |
|
18.03
-2.79%
|
18.55
+444.48%
|
3.41
-41.34%
|
5.81
|
| Leases |
|
2.34
+0.78%
|
2.32
+1.80%
|
2.28
+0.00%
|
2.28
|
| Goodwill And Other Intangible Assets |
|
2.33
+0.00%
|
2.33
-1.31%
|
2.36
-4.95%
|
2.49
|
| Goodwill |
|
2.33
+0.00%
|
2.33
+0.00%
|
2.33
+0.00%
|
2.33
|
| Other Intangible Assets |
|
—
|
—
|
0.03
-79.87%
|
0.15
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
14.39
+142.91%
|
5.92
|
| Other Non Current Assets |
|
5.03
+78.42%
|
2.82
-11.16%
|
3.17
-45.44%
|
5.81
|
| Total Liabilities Net Minority Interest |
|
75.17
-2.42%
|
77.04
+29.55%
|
59.47
+49.91%
|
39.67
|
| Current Liabilities |
|
20.06
-17.92%
|
24.44
+5.53%
|
23.16
+25.23%
|
18.49
|
| Payables And Accrued Expenses |
|
15.18
+12.79%
|
13.45
+35.23%
|
9.95
-1.30%
|
10.08
|
| Payables |
|
5.18
+10.12%
|
4.70
+99.87%
|
2.35
-2.12%
|
2.40
|
| Accounts Payable |
|
3.90
+2.04%
|
3.83
+155.64%
|
1.50
-14.85%
|
1.76
|
| Current Accrued Expenses |
|
10.00
+14.23%
|
8.75
+15.21%
|
7.60
-1.04%
|
7.68
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.55
-48.52%
|
6.89
-12.46%
|
7.88
+58.36%
|
4.97
|
| Total Tax Payable |
|
1.27
+45.43%
|
0.88
+2.34%
|
0.86
+32.51%
|
0.65
|
| Income Tax Payable |
|
0.26
+436.73%
|
0.05
-47.31%
|
0.09
+389.47%
|
0.02
|
| Current Debt And Capital Lease Obligation |
|
1.32
-66.72%
|
3.95
-24.38%
|
5.23
+57.55%
|
3.32
|
| Current Debt |
|
0.11
-96.66%
|
3.18
+47.38%
|
2.15
+2294.44%
|
0.09
|
| Other Current Borrowings |
|
0.11
-96.66%
|
3.18
+47.38%
|
2.15
+2294.44%
|
0.09
|
| Current Capital Lease Obligation |
|
1.21
+55.53%
|
0.78
-74.69%
|
3.07
-4.80%
|
3.23
|
| Current Deferred Liabilities |
|
0.02
-86.67%
|
0.14
+29.81%
|
0.10
-13.33%
|
0.12
|
| Current Deferred Revenue |
|
0.02
-86.67%
|
0.14
+29.81%
|
0.10
-13.33%
|
0.12
|
| Total Non Current Liabilities Net Minority Interest |
|
55.12
+4.78%
|
52.60
+44.88%
|
36.31
+71.45%
|
21.18
|
| Long Term Debt And Capital Lease Obligation |
|
55.05
+4.82%
|
52.52
+45.09%
|
36.20
+71.68%
|
21.08
|
| Long Term Debt |
|
36.99
+8.78%
|
34.00
-3.10%
|
35.09
+103.60%
|
17.23
|
| Long Term Capital Lease Obligation |
|
18.06
-2.46%
|
18.52
+1574.05%
|
1.11
-71.27%
|
3.85
|
| Non Current Deferred Liabilities |
|
0.07
-20.69%
|
0.09
-23.68%
|
0.11
+21.28%
|
0.09
|
| Non Current Deferred Taxes Liabilities |
|
0.07
-20.69%
|
0.09
-23.68%
|
0.11
+21.28%
|
0.09
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
54.12
-36.93%
|
85.81
-27.47%
|
118.31
-23.18%
|
154.01
|
| Common Stock Equity |
|
54.12
-36.93%
|
85.81
-27.47%
|
118.31
-23.18%
|
154.01
|
| Capital Stock |
|
0.04
+5.00%
|
0.04
+2.56%
|
0.04
+2.63%
|
0.04
|
| Common Stock |
|
0.04
+5.00%
|
0.04
+2.56%
|
0.04
+2.63%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
41.67
+4.74%
|
39.79
+3.30%
|
38.52
+2.56%
|
37.56
|
| Ordinary Shares Number |
|
41.67
+4.74%
|
39.79
+3.30%
|
38.52
+2.56%
|
37.56
|
| Additional Paid In Capital |
|
573.27
+4.00%
|
551.21
+4.63%
|
526.80
+4.79%
|
502.71
|
| Retained Earnings |
|
-521.56
-11.55%
|
-467.56
-13.72%
|
-411.16
-17.37%
|
-350.32
|
| Gains Losses Not Affecting Retained Earnings |
|
2.36
+11.69%
|
2.11
-19.96%
|
2.64
+67.62%
|
1.57
|
| Other Equity Adjustments |
|
2.36
+11.69%
|
2.11
-19.96%
|
2.64
+67.62%
|
1.57
|
| Total Equity Gross Minority Interest |
|
54.12
-36.93%
|
85.81
-27.47%
|
118.31
-23.18%
|
154.01
|
| Total Capitalization |
|
91.11
-23.96%
|
119.81
-21.90%
|
153.40
-10.42%
|
171.24
|
| Working Capital |
|
81.63
-27.00%
|
111.81
-12.14%
|
127.27
-15.42%
|
150.46
|
| Invested Capital |
|
91.21
-25.84%
|
122.99
-20.94%
|
155.56
-9.21%
|
171.33
|
| Total Debt |
|
56.36
-0.19%
|
56.47
+36.32%
|
41.42
+69.76%
|
24.40
|
| Capital Lease Obligations |
|
19.27
-0.12%
|
19.29
+361.56%
|
4.18
-40.94%
|
7.08
|
| Net Tangible Assets |
|
51.78
-37.97%
|
83.48
-28.01%
|
115.95
-23.47%
|
151.52
|
| Tangible Book Value |
|
51.78
-37.97%
|
83.48
-28.01%
|
115.95
-23.47%
|
151.52
|
| Available For Sale Securities |
|
—
|
—
|
14.39
+142.91%
|
5.92
|
| Investmentin Financial Assets |
|
—
|
0.00
-100.00%
|
14.39
+142.91%
|
5.92
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-32.38
-2.66%
|
-31.54
+16.15%
|
-37.61
+16.58%
|
-45.08
|
| Cash Flow From Continuing Operating Activities |
|
-32.38
-2.66%
|
-31.54
+16.15%
|
-37.61
+16.58%
|
-45.08
|
| Net Income From Continuing Operations |
|
-54.00
+4.24%
|
-56.39
+7.31%
|
-60.84
-3.26%
|
-58.92
|
| Depreciation Amortization Depletion |
|
1.05
-29.40%
|
1.49
-3.55%
|
1.55
+2.31%
|
1.51
|
| Depreciation And Amortization |
|
1.05
-29.40%
|
1.49
-3.55%
|
1.55
+2.31%
|
1.51
|
| Other Non Cash Items |
|
1.50
-20.83%
|
1.90
-30.65%
|
2.73
+7.05%
|
2.55
|
| Stock Based Compensation |
|
21.23
-7.50%
|
22.95
+3.86%
|
22.10
+34.39%
|
16.45
|
| Provisionand Write Offof Assets |
|
0.00
-100.00%
|
0.04
+167.80%
|
-0.06
-209.26%
|
0.05
|
| Asset Impairment Charge |
|
0.14
-92.02%
|
1.79
+253.45%
|
0.51
+4.54%
|
0.48
|
| Operating Gains Losses |
|
—
|
—
|
-0.01
-314.29%
|
0.01
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
+100.00%
|
-0.01
-314.29%
|
0.01
|
| Change In Working Capital |
|
-1.93
-13.04%
|
-1.70
+33.42%
|
-2.56
+63.53%
|
-7.01
|
| Change In Receivables |
|
1.07
+182.19%
|
-1.31
+57.86%
|
-3.10
-41.74%
|
-2.19
|
| Changes In Account Receivables |
|
1.07
+182.19%
|
-1.31
+57.86%
|
-3.10
-41.74%
|
-2.19
|
| Change In Inventory |
|
-0.77
-234.06%
|
-0.23
-124.95%
|
0.92
+125.23%
|
-3.64
|
| Change In Prepaid Assets |
|
0.81
+286.47%
|
-0.44
-664.91%
|
-0.06
-107.31%
|
0.78
|
| Change In Payables And Accrued Expense |
|
-1.81
-167.17%
|
2.70
-6.80%
|
2.90
+965.81%
|
0.27
|
| Change In Accrued Expense |
|
-2.28
-593.29%
|
0.46
-85.45%
|
3.18
+2031.54%
|
0.15
|
| Change In Payable |
|
0.46
-79.29%
|
2.24
+908.66%
|
-0.28
-325.20%
|
0.12
|
| Change In Account Payable |
|
0.27
-88.15%
|
2.28
+760.29%
|
-0.34
-239.68%
|
0.25
|
| Change In Other Working Capital |
|
-0.14
-750.00%
|
-0.02
-500.00%
|
0.00
-50.00%
|
0.01
|
| Change In Other Current Assets |
|
-0.14
+73.99%
|
-0.55
-1416.67%
|
-0.04
+26.53%
|
-0.05
|
| Change In Other Current Liabilities |
|
-0.95
+48.93%
|
-1.87
+41.23%
|
-3.18
-44.83%
|
-2.20
|
| Investing Cash Flow |
|
30.48
+74.42%
|
17.48
+970.75%
|
-2.01
+52.50%
|
-4.22
|
| Cash Flow From Continuing Investing Activities |
|
30.48
+74.42%
|
17.48
+970.75%
|
-2.01
+52.50%
|
-4.22
|
| Net PPE Purchase And Sale |
|
-0.45
+68.76%
|
-1.45
-79.31%
|
-0.81
+38.77%
|
-1.32
|
| Purchase Of PPE |
|
-0.45
+68.76%
|
-1.45
-79.31%
|
-0.81
+38.77%
|
-1.32
|
| Capital Expenditure |
|
-0.45
+68.76%
|
-1.45
-79.31%
|
-0.81
+38.77%
|
-1.32
|
| Net Investment Purchase And Sale |
|
30.93
+63.47%
|
18.92
+1676.92%
|
-1.20
+58.72%
|
-2.91
|
| Purchase Of Investment |
|
-5.65
+79.76%
|
-27.91
+39.58%
|
-46.20
+2.09%
|
-47.19
|
| Sale Of Investment |
|
36.59
-21.89%
|
46.84
+4.08%
|
45.00
+1.63%
|
44.28
|
| Financing Cash Flow |
|
0.83
-38.88%
|
1.36
-93.63%
|
21.40
+784.66%
|
2.42
|
| Cash Flow From Continuing Financing Activities |
|
0.83
-38.88%
|
1.36
-93.63%
|
21.40
+784.66%
|
2.42
|
| Net Issuance Payments Of Debt |
|
-0.10
-5.26%
|
-0.10
-100.48%
|
19.91
+22980.46%
|
-0.09
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
20.00
|
0.00
|
| Repayment Of Debt |
|
-0.10
-5.26%
|
-0.10
-1.06%
|
-0.09
-8.05%
|
-0.09
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
20.00
|
0.00
|
| Long Term Debt Payments |
|
-0.10
-5.26%
|
-0.10
-1.06%
|
-0.09
-8.05%
|
-0.09
|
| Net Long Term Debt Issuance |
|
-0.10
-5.26%
|
-0.10
-100.48%
|
19.91
+22980.46%
|
-0.09
|
| Net Common Stock Issuance |
|
—
|
—
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
1.00
-31.21%
|
1.46
-2.41%
|
1.49
-41.62%
|
2.56
|
| Net Other Financing Charges |
|
-0.07
|
—
|
—
|
-0.05
|
| Changes In Cash |
|
-1.06
+91.64%
|
-12.70
+30.30%
|
-18.22
+61.15%
|
-46.89
|
| Effect Of Exchange Rate Changes |
|
-0.09
-221.05%
|
0.08
+123.53%
|
0.03
-76.55%
|
0.14
|
| Beginning Cash Position |
|
71.16
-15.06%
|
83.78
-17.83%
|
101.97
-31.43%
|
148.71
|
| End Cash Position |
|
70.01
-1.62%
|
71.16
-15.06%
|
83.78
-17.83%
|
101.97
|
| Free Cash Flow |
|
-32.83
+0.47%
|
-32.98
+14.14%
|
-38.42
+17.21%
|
-46.40
|
| Interest Paid Supplemental Data |
|
3.11
-10.60%
|
3.48
+16.69%
|
2.98
+252.30%
|
0.85
|
| Income Tax Paid Supplemental Data |
|
0.47
-15.83%
|
0.56
+18.05%
|
0.47
+18.34%
|
0.40
|
| Amortization Of Securities |
|
-0.38
+76.55%
|
-1.62
-57.66%
|
-1.02
-402.45%
|
-0.20
|
| Change In Income Tax Payable |
|
0.19
+610.53%
|
-0.04
-155.88%
|
0.07
+154.84%
|
-0.12
|
| Change In Tax Payable |
|
0.19
+610.53%
|
-0.04
-155.88%
|
0.07
+154.84%
|
-0.12
|
| Common Stock Issuance |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-10 View
- 8-K2026-03-05 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 8-K2026-03-04 View
- 42025-12-09 View
- 42025-12-03 View
- 42025-12-03 View
- 42025-12-03 View
- 42025-12-03 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
- 8-K2025-10-27 View
- 42025-09-03 View
- 42025-09-03 View
- 42025-09-03 View
- 42025-09-03 View
- 10-Q2025-08-01 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|